Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.
about
The dual role of complement in cancer and its implication in anti-tumor therapyC1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation.Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.Role of complement in glomerular diseases.Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1.New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma.Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.Innate immune mediators in cancer: between defense and resistance.Reconceptualizing cancer immunotherapy based on plant production systems.C1-inactivator is upregulated in glioblastoma.Real-time Characterization of Antibody Binding to Receptors on Living Immune Cells.An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity.N-glycan engineering of a plant-produced anti-CD20-hIL-2 immunocytokine significantly enhances its effector functions.IgG Fc engineering to modulate antibody effector functions.Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas.[The complement system: a double edge sword in tumor progression].Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
P2860
Q26738682-DF3EBA46-C0A6-4C2A-8C69-34AA52F6B3E7Q36541076-6CF65CB1-74DB-487C-829E-2EDC17BB9E95Q38542034-AC22FFB5-50B2-462A-96BE-DCBD3BB5E612Q38591917-2FFEBE74-3ACE-4A94-8357-405236E1B2B4Q38722574-6E5CC928-617B-447B-B241-817099C4ADE4Q38847426-EE7097A5-08D8-4A82-BD69-FE0B0D08F560Q38895520-9E87A3D5-F4E5-4972-9408-2A7BA4314C90Q38916529-3735D46A-3E7F-4417-AAD5-BEA53AEB277CQ38991015-912A7919-BFCE-4B1C-92D0-34549DE43E8DQ40051873-8D072D4E-5118-4B83-AFDB-294188084115Q41577019-B54E6F66-AFA0-47B2-98B9-470D696EA5B7Q42290751-36098AA2-0885-4EFB-9BF3-34AB0C992126Q42660174-B1E23347-343E-4A70-9C06-46158C927A9DQ47311471-BC9A4310-540B-45E7-8EDD-B8ED163774B4Q47593242-7EB0C443-3944-44F6-8DC5-FD03665C0DEAQ49672464-182F9C5C-4021-4869-9DB7-59945955E42EQ50243745-D23139D6-84CA-46C5-ACEB-0355ABC37D26Q53507006-6176CEAC-A2D5-4441-94E9-E5490763AB6CQ57191729-1865EBED-6447-49F6-AA49-AA7CE4842938
P2860
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Regulation of complement and m ...... al antibody therapy of cancer.
@en
type
label
Regulation of complement and m ...... al antibody therapy of cancer.
@en
prefLabel
Regulation of complement and m ...... al antibody therapy of cancer.
@en
P2860
P921
P356
P1476
Regulation of complement and m ...... al antibody therapy of cancer.
@en
P2093
Peter Boross
Saskia Meyer
P2860
P304
P356
10.4161/MABS.29670
P5008
P577
2014-10-30T00:00:00Z